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cTo the Editor – The widely used Functional Assessment of Cancer Ther-
apy - Prostate Cancer (FACT-P) consists of the Functional Assessment of
Cancer Therapy – General (FACT-G) and a prostate cancer subscale. In
its second version, the FACT-G consists of five subscales measuring
physical, functional,social/family,andemotionalwell-beinginaddition
to satisfaction with the doctor-patient relationship (the current version
4 of the FACT-G no longer includes a relationship with doctor subscale).
The prostate cancer subscale of the FACT-P includes 12 items specifi-
cally designed to measure important symptoms and concerns specific
to men with prostate cancer. In an article published in 2007, Wu et al. [1]
described an algorithm for mapping FACT-P scores to EuroQol five-di-
mensional questionnaire scores.
Recently, we used this algorithm to map the FACT-P data to the
EuroQol five-dimensional questionnaire by using data from a clin-
ical trial. A discrepancy, however, was discovered in the published
conversion equation. Specifically, our mapping effort was produc-
ing out-of-range (i.e., greater than 1) mean EuroQol five-dimen-
sional questionnaire values.
We tried to reproduce the average utility value in the Wu et al. pub-
lication by inserting the identical input data that Wu et al. used (Fig. 1
hows FACT-P variables; Fig. 2 shows baseline patient characteristics)
nto the mapping equation presented (Fig. 3; “Excluding EORTC” col-
mn). In doing this, we found a second discrepancy in the Wu et al.
ublication. In Figure 2, the excerpt from the Wu et al. publication cites
he mean body mass index (BMI) at 72.4. It is clear that this is a graphical
rror (the mean age value is used for mean BMI as well). To confirm this,
e consulted the source publication for the input data that Wu et al.
sed, a summary of mCRPC observational study quality-of-life findings
y Sullivan et al [2]. In the Sullivan et al. article, we found that the mean
MI was 27, and confirmed the mean age to be 72.4 years. When apply-
ng input data from Table 1 and using average characteristics of the
tudy population published by Wu et al. (including the corrected value
or BMI) to the mapping algorithm, we arrived at an average mapped
tility of 1.11 compared with the value of 0.62 reported by Wu et al.
As a solution, we adjusted the mapping equation by removing the
ge and BMI prediction variables, adding their effect into the intercept
erm,andrecalibratingthe intercept termonthebasisof inputvariables
nd equation result listed in the Wu et al. article (Figs. 1 and 2).
Taking this approach required the assumption that the age and BMI
een in the clinical trial are identical to those seen in the Sullivan et al.
eport (source data for the Wu et al. algorithm). In the clinical trial, the
ean age was 69.0 years. In the Sullivan et al. article, the mean age was
2.4 years. The mean BMI in the clinical trial was 27.6, while the mean
MI in the Sullivan et al. article was 27. Therefore, the assumption of
imilar age and BMI in the clinical trial and Sullivan et al. article appears
o hold. By removing the coefficients for age and BMI from the Wu et al.
apping equation and recalibrating to a mean utility of 0.62, the result-
ng intercept was0.333.
Insummary, theoriginalandmodifiedmappingequationsare listed
elow:Original
Utility  0.440  0.027  GPT  0.003  GST  0.009  GET 
.002  GFT  0.009  ADT  0.009  (Age)  0.002  (BMI) 
0.015 (Australia) 0.057 (Canada) 0.011 (France) 0.027
(Germany)  0.076  (Italy)  0.001  (United Kingdom)  0.000
 (United States)
Modified
Utility  0.333  0.027  GPT  0.003  GST  0.009  GET 
.002  GFT  0.009  ADT  0.015  (Australia)  0.057 
Canada)  0.011  (France)  0.027  (Germany)  0.076  (Italy)
0.001  (United Kingdom)  0.000  (United States)
ACT-P subscore abbreviations: ADT, FACT-P subscale; GET, emo-
ional well-being; GFT, functional well-being; GPT, physical well-
eing; GST, social well-being.
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784 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 8 3 – 7 8 8Fig. 1 – FACT-P inputs. Reprinted from Value in Health, 10(5),
Wu EQ, Mulani P, Farrell MH, Sleep D, Mapping FACT-P and
EORTC QLQ-C30 to patient health status measured by EQ-5D
in metastatic hormone-refractory prostate cancer patients,
408-414, 2007, with permission from Elsevier.Fig. 2 – Patient characteristics inputs. Reprinted from Value
in Health, 10(5), Wu EQ, Mulani P, Farrell MH, Sleep D,
Mapping FACT-P and EORTC QLQ-C30 to patient health
status measured by EQ-5D in metastatic hormone-
refractory prostate cancer patients, 408-414, 2007, with
permission from Elsevier.Fig. 3 – FACT-P to EuroQol five-dimensional
questionnaire mapping equation. Reprinted from Value
in Health, 10(5), Wu EQ, Mulani P, Farrell MH, Sleep D,
Mapping FACT-P and EORTC QLQ-C30 to patient health
status measured by EQ-5D in metastatic hormone-
refractory prostate cancer patients, 408-414, 2007, with
permission from Elsevier.
